Rise and shine, everyone, another busy day is on the way. We can tell because our short person has left a cloud of dust after hastily departing for the local schoolhouse for another day of enlightened learning. As for us, we are firing up the trusty coffee kettle and trying to get organized for another round of phone calls and the like. Perhaps you can relate. Meanwhile, we have also assembled a few items of interest to help you with your own hectic schedule. Hope you conquer the world today and drop us a line if something saucy occurs.

President Trump is considering executive action to cut drug prices ahead of the 2020 election and tries to rebut Democratic criticism that his policies have hurt U.S. health care, Bloomberg News reports. If he proceeds, Trump would force drug makers to accept lower payments from Medicare for treatments administered in physician offices. The rule would apply to certain drugs bought by the “Part B” section of Medicare, the program for the elderly and disabled.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy